Investors & Media

Corporate Profile

We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

Investor Overview

Common Stock


Change (%)


Data as of: 01/22/19 11:55 am EST.

Copyright Nasdaq. Minimum 15 minutes delayed.

Investor Contact

Heather Leo
Associate, Investor Relations

(646) 490-2965

Media Contact

Kelly Boothe
Group Director, W2O Group

(415) 946-1076